<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02259816</url>
  </required_header>
  <id_info>
    <org_study_id>1235.2</org_study_id>
    <nct_id>NCT02259816</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers</brief_title>
  <official_title>Pharmacokinetics of Repeated Oral Doses of 80 mg Telmisartan (Micardis®) at Steady State Alone and in Combination With Repeated Oral Doses of Amlodipine 10 mg (Norvasc®) at Steady State. A Two-way Crossover, Open, Randomised Design Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the steady state pharmacokinetics of 80 mg telmisartan alone and in
      combination with repeated doses of 10 mg amlodipine
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of telmisartan in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)</measure>
    <time_frame>up to 15 days after first administration of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of telmisartan in plasma at steady state over a uniform dosing interval τ (Cmax,ss)</measure>
    <time_frame>up to 15 days after first administration of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss for amlodipine</measure>
    <time_frame>up to 15 days after first administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss for amlodipine</measure>
    <time_frame>up to 15 days after first administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>up to 12 hours after first administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to maximum measured concentration on plasma (tmax)</measure>
    <time_frame>up to 12 hours after first administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve over a uniform dosing interval τ after administration of the first dose; corresponds to AUC0-24h (AUCτ,1)</measure>
    <time_frame>up to 12 hours after first administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose concentration of the analyte in plasma immediately before the administration of the next dose N (Cpre,N)</measure>
    <time_frame>pre-dose on days 2-9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from last dosing to the maximum concentration of the analyte in plasma at steady state (tmax,ss)</measure>
    <time_frame>up to 144 hours after last administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)</measure>
    <time_frame>up to 144 hours after last administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant in plasma at steady state (λz,ss)</measure>
    <time_frame>up to 144 hours after last administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma at steady state (t1/2, ss)</measure>
    <time_frame>up to 144 hours after last administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of the analyte in the body at steady state after oral administration (MRTpo,ss)</measure>
    <time_frame>up to 144 hours after last administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of the analyte in plasma at steady state after extravascular multiple dose administration (CL/F,ss)</measure>
    <time_frame>up to 144 hours after last administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of the analyte in plasma at steady state after extravascular multiple dose administration (Vz/F,ss)</measure>
    <time_frame>up to 144 hours after last administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of the analyte in plasma based on AUC over a uniform dosing interval after the first and last doses (RA, AUC)</measure>
    <time_frame>up to 15 days after first administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of the analyte in plasma based on Cmax over a uniform dosing interval after the last and first doses (RA,Cmax)</measure>
    <time_frame>up to 15 days after first administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 80 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>within 14 days after last trial procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan and amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_label>Telmisartan and amlodipine</arm_group_label>
    <other_name>Micardis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <arm_group_label>Telmisartan and amlodipine</arm_group_label>
    <other_name>Norvasc®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females according to the following criteria:

             Based upon a complete medical history, including the physical examination, vital signs
             (BP, PR), 12-lead ECG, clinical laboratory tests

          2. Age ≥18 and Age ≤50 years

          3. BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice and the local legislation

        Exclusion Criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Surgery of the gastrointestinal tract (except appendectomy)

          5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          6. History of relevant orthostatic hypotension, fainting spells or blackouts

          7. Chronic or relevant acute infections

          8. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          9. Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

         10. Use of drugs which might reasonably influence the results of the trial or that prolong
             the QT/corrected QT interval based on the knowledge at the time of protocol
             preparation within 10 days prior to administration or during the trial

         11. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         12. Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

         13. Inability to refrain from smoking on trial days

         14. Alcohol abuse (more than 60 g/day)

         15. Drug abuse

         16. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         17. Excessive physical activities (within one week prior to administration or during the
             trial)

         18. Any laboratory value outside the reference range that is of clinical relevance

         19. Inability to comply with dietary regimen of trial site

         20. Any history of relevant low blood pressure

         21. Supine blood pressure at screening of systolic &lt;110 mm Hg and/or diastolic &lt;60 mm Hg

         22. History of urticaria

             For female subjects:

         23. Pregnancy or planning to become pregnant within 2 months of study completion

         24. Positive pregnancy test

         25. No adequate contraception e.g. sterilisation, intrauterine device, have not been using
             a barrier method of contraception for at least 3 months prior to participation in the
             study

         26. Are not willing or are unable to use a reliable method of barrier contraception (such
             as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during
             and up to 2 months after completion/termination of the trial

         27. Chronic use of oral contraception or hormone replacement containing ethinyl estradiol
             as the only method of contraception

         28. Partner is unwilling to use condoms

         29. Lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2014</study_first_posted>
  <last_update_submitted>October 6, 2014</last_update_submitted>
  <last_update_submitted_qc>October 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

